Revisions to Financial Reporting and Calendar
The board of Pharma Equity Group A/S has recently made the strategic decision to submit only half-yearly financial reports moving forward. This adjustment reflects a shift in focus towards more impactful reporting. As a result, the financial calendar for 2025 has been updated to better align with these new reporting practices.
Updated Financial Calendar for 2025
The updated financial calendar provides essential dates for shareholders and investors, ensuring they remain informed about critical company developments.
Key Dates
Here are the significant dates for the financial calendar:
- March 4: Deadline for shareholder proposals for the Annual General Meeting
- March 20: Annual Report for 2024 publication
- April 16: Annual General Meeting
- August 14: Interim Report for the six-month period ending June 30, 2025
Investor Relations Contact Details
Pharma Equity Group values its relationship with investors. For inquiries about investor relations and stock market issues, interested parties can reach out directly. Thomas Kaas Selsø, CEO, is available at +45 4022 2114 or via email. He looks forward to addressing any questions regarding the company's advancements and strategic direction.
Company Overview
Pharma Equity Group is a publicly traded company listed on the Nasdaq Copenhagen stock exchange. The firm is dedicated to supporting medical projects through its subsidiary, Reponex Pharmaceuticals A/S. With a strong commitment to enhancing healthcare, Pharma Equity Group aims to bring substantial value to the medical developments led by Reponex Pharmaceuticals.
Strategic Focus on Medical Advancements
The company is devoted to providing comprehensive resources, expertise, and advocacy necessary for the success of its subsidiaries' projects. Pharma Equity Group prioritizes the development of innovative medical solutions and breakthrough therapies. This strategic partnership approach not only reinforces their current projects but also keeps the door open for future investments aimed at sustained growth.
For further information and additional updates, interested individuals may visit the company's website, where all of its announcements and communications regarding the future can be found.
Frequently Asked Questions
What is the new reporting strategy of Pharma Equity Group?
Pharma Equity Group has decided to issue half-yearly financial reports instead of quarterly reports, aiming for more substantial communication with shareholders.
How can I contact Pharma Equity Group for investor relations?
Investors can reach Thomas Kaas Selsø, CEO, at +45 4022 2114 or via email for any queries regarding shareholder matters.
When is the Annual General Meeting in 2025?
The Annual General Meeting is scheduled for April 16, 2025, as part of the updated financial calendar.
What key financial document is released on March 20, 2025?
On March 20, 2025, Pharma Equity Group will release its Annual Report for the year 2024.
Where can I find more information about Pharma Equity Group?
Additional information can be found on the company’s website, where they publish ongoing announcements and updates about their projects and financial performance.
